Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Organisation › Details

Cardiorentis (Group)

Cardiorentis is a private biopharmaceutical company headquartered in Zug, Switzerland. Cardiorentis is committed to bringing novel therapies to the treatment of heart failure and related cardiovascular diseases. The company's disease-based technology platform integrates expertise in protein biology to identify novel targets and rationally design small molecule compounds and peptides for markets with unmet medical needs. *

 

Period Start 2010-01-01 established
Products Industry cardiovascular drug
  Industry 2 ularitide
Persons Person Holzmeister, Johannes (Dinaqor 202009 CEO + Co-Founder + Cardiorentis AG 201409 CEO + CMO)
  Person 2 Schnee, Elmar (Cardiorentis 201110– CEO before Merck Serono S.A. 200701 CEO before Merck KGaA)
     
Region Region Zug ZG
  Country Switzerland
  Street 74 Steinhauserstr.
  City 6300 Zug ZG
  Tel +41-41-748-6030
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
     
    * Document for �About Section�: Cardiorentis AG. (9/17/14). "Press Release: Cardiorentis Announces Euro 45 Million Financing with HealthCare Royalty Partners to Fund Ularitide Registration Program in Acute Heart Failure". Zug.
     
   
Record changed: 2019-05-30

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Cardiorentis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top